-+ 0.00%
-+ 0.00%
-+ 0.00%

FibroBiologics files patent for engineered cells designed to produce GLP-1 inside body

PUBT·10/07/2026 12:31:45
Listen to the news
FibroBiologics files patent for engineered cells designed to produce GLP-1 inside body
  • FibroBiologics filed a U.S. patent application for engineered cells designed to continuously produce GLP-1 class peptides inside the body.
  • Approach uses fibroblasts or other cells formed into spheroids or organoids to secrete GLP-1, GIP, or GLP-2 over time.
  • Technology targets a one-time administration to replace repeated injections or pills, aiming for steadier exposure and improved compliance.
  • Patent also covers dual or triple agonist secretion with adjustable hormone ratios, using mixed cell populations or single cells.
  • Application includes control features such as immune-evasion, inducible kill switches, safe-harbor gene insertion, or retrievable encapsulation devices.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Fibrobiologics Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: DA65633) on October 07, 2026, and is solely responsible for the information contained therein.